Incyte Corporation (INCY)
Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Q4 Earnings Lag Estimates
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming patent losses on top-seller Jakafi.
Here's Why Incyte (INCY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Incyte (INCY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Incyte (INCY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Investors Should Know Before Buying Incyte
Incyte offers a compelling risk-adjusted return profile, outperforming healthcare benchmarks with robust growth and moderate volatility. INCY is successfully transitioning from Jakafi dependence to a diversified Hematology/Oncology, Immunology, and Autoimmunity portfolio, driving double-digit revenue growth. Third-quarter 2025 revenue rose 20% YoY to $1.37B, and operating income was up 204%.
